118 related articles for article (PubMed ID: 37106570)
1. Prediction model on disease recurrence for low risk resected stage I lung adenocarcinoma.
Kwok WC; Ma TF; Ho JCM; Lam DCL; Sit KY; Ip MSM; Au TWK; Tam TCC
Respirology; 2023 Jul; 28(7):669-676. PubMed ID: 37106570
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma.
Yang L; Zhang J; Yang G; Xu H; Lin J; Shao L; Li J; Guo C; Du Y; Guo L; Li X; Han-Zhang H; Wang C; Chuai S; Ye J; Kang Q; Liu H; Ying J; Wang Y
Theranostics; 2020; 10(17):7635-7644. PubMed ID: 32685009
[TBL] [Abstract][Full Text] [Related]
3. Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection.
Jiang MQ; Qian LQ; Shen YJ; Fu YY; Feng W; Ding ZP; Han YC; Fu XL
Neoplasia; 2024 Apr; 50():100979. PubMed ID: 38387107
[TBL] [Abstract][Full Text] [Related]
4. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
6. Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.
Liu W; Shao Y; Guan B; Hao J; Cheng X; Ji K; Wang K
Int J Clin Exp Pathol; 2015; 8(9):11268-77. PubMed ID: 26617851
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain-only relapse versus synchronous extracranial relapse.
Xu F; Li J; Xing P; Liu Y; Wang Y
Cancer Med; 2023 Jun; 12(11):12495-12503. PubMed ID: 37062064
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.
Li Y; Zhao J; Zhao Y; Li R; Dong X; Yao X; Xia Z; Xu Y; Li Y
Cancer Med; 2024 Feb; 13(3):e7030. PubMed ID: 38400663
[TBL] [Abstract][Full Text] [Related]
9. Early Distant Recurrence in Patients With Resected Stage I Lung Cancer: A Case Series of "Blast Metastasis".
Ekeke CN; Mitchell C; Schuchert M; Dhupar R; Luketich JD; Okusanya OT
Clin Lung Cancer; 2021 Jan; 22(1):e132-e135. PubMed ID: 33144072
[TBL] [Abstract][Full Text] [Related]
10. [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
Xu L; Guo R
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):852-861. PubMed ID: 36617471
[TBL] [Abstract][Full Text] [Related]
11. Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm.
Huang CS; Hsu PK; Chen CK; Yeh YC; Hsu HS; Shih CC; Huang BS
Thorac Cancer; 2020 Apr; 11(4):907-917. PubMed ID: 32037690
[TBL] [Abstract][Full Text] [Related]
12. Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer.
Wu CF; Fu JY; Yeh CJ; Liu YH; Hsieh MJ; Wu YC; Wu CY; Tsai YH; Chou WC
Medicine (Baltimore); 2015 Aug; 94(32):e1337. PubMed ID: 26266381
[TBL] [Abstract][Full Text] [Related]
13. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
[TBL] [Abstract][Full Text] [Related]
16. Positive intraoperative pleural lavage cytology is a predictive marker of disease recurrence in stage I lung adenocarcinoma.
Yanagawa N; Shiono S; Abiko M; Abe M; Watanabe K; Watanabe I; Uematsu M; Ogata SY; Sato T; Tamura G
Interact Cardiovasc Thorac Surg; 2014 May; 18(5):621-5. PubMed ID: 24532312
[TBL] [Abstract][Full Text] [Related]
17. Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model.
Jang HJ; Cho S; Kim K; Jheon S; Yang HC; Kim DK
Cancer Res Treat; 2017 Oct; 49(4):898-905. PubMed ID: 28111426
[TBL] [Abstract][Full Text] [Related]
18. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
[TBL] [Abstract][Full Text] [Related]
19. Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: A retrospective observational study.
Shah A; Apple J; Belli AJ; Barcellos A; Hansen E; Fernandes LL; Zettler CM; Wang CK
Cancer Treat Res Commun; 2023; 36():100742. PubMed ID: 37478531
[TBL] [Abstract][Full Text] [Related]
20. A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer.
Goodgame B; Viswanathan A; Miller CR; Gao F; Meyers B; Battafarano RJ; Patterson A; Cooper J; Guthrie TJ; Bradley J; Pillot G; Govindan R
Am J Clin Oncol; 2008 Feb; 31(1):22-8. PubMed ID: 18376223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
